Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Science

Contact

Board

Company Overview

Team

Corporate Governance

Corporate Directory

Values

Clinical Advisers

About Us

Video Updates

Presentations

In the News

Communication

Updates

US Shareholders

Investor FAQs

Shareholder Services

Research Reports

Reports

Announcements

Investor Fact Sheet

Top 20 Shareholders

Share Price

Investor Centre

Clinical Trial

Webinars

Home

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia has received US ethics approval to initiate a Phase 2 clinical trial of narmafotinib in combination with FOLFIRINOX chemotherapy for advanced pancreatic cancer patients.

The trial will explore the combination of narmafotinib with the chemotherapy FOLFIRINOX, which is the preferred first-line treatment for newly diagnosed advanced pancreatic cancer patients in the US.

The Phase 2a trial will recruit 60-70 patients across up to six US sites and two Australian sites.

Amplia CEO and MD Dr Chris Burns commented:

"Receiving the protocol approval from the IRB is a critical step in initiating the US trial of narmafotinib in combination with FOLFIRINOX. Importantly, results from this trial will complement the existing positive data emerging from our current ACCENT trial, aiming to establish narmafotinib as the optimal combination partner for chemotherapy in this challenging disease."

The Company's FAK inhibitor narmafotinib has already demonstrated promising activity in the ACCENT trial, with two complete responses recorded – a rare outcome in advanced pancreatic cancer.

Amplia Receives US Ethics Clearance For Pancreatic Cancer Trial